Stocks and Investing
Stocks and Investing
Tue, March 22, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, March 21, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Carter Gould Maintained (VOR) at Buy with Decreased Target to $26 on, Mar 21st, 2022
Carter Gould of Barclays, Maintained "Vor Biopharma Inc." (VOR) at Buy with Decreased Target from $56 to $26 on, Mar 21st, 2022.
Carter has made no other calls on VOR in the last 4 months.
There are 4 other peers that have a rating on VOR. Out of the 4 peers that are also analyzing VOR, 0 agree with Carter's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Carter
- Silvan Tuerkcan of "JMP Securities" Maintained at Buy with Decreased Target to $30 on, Wednesday, March 16th, 2022
- Swayampakula Ramakanth of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $26 on, Friday, December 17th, 2021
- Jack Allen of "Baird" Initiated at Buy and Held Target at $38 on, Friday, December 3rd, 2021
- Matthew Biegler of "Oppenheimer" Initiated at Buy and Held Target at $30 on, Thursday, December 2nd, 2021
Contributing Sources